To include your compound in the COVID-19 Resource Center, submit it here.

Breo Ellipta misses in Phase III SUMMIT study

Theravance Inc. (NASDAQ:THRX) tumbled $2.43 (15%) to $13.56 on Tuesday after Breo Ellipta fluticasone furoate/vilanterol failed to significantly improve survival

Read the full 203 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE